It is hoped that such approaches may be combined with biomarkers (e.g., CSF tau and ß-amyloid levels or molecular imaging) to assess how LC neurodegeneration may drive clinical and pathological manifestations of AD. The gene discussed is MAPT; the disease is Alzheimer disease.